Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

  • STATUS
    Recruiting
  • participants needed
    6
  • sponsor
    AstraZeneca
Send
Updated on 19 February 2024
See if I qualify

Summary

This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort to confirm the tolerability.

Description

Objectives

Primary objective:

To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for adavosertib

Secondary objective:

To determine the PK profile of adavosertib To describe adavosertib's preliminary anti-tumour activity using the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1

Overall design:

This is a phase I, open-label study to assess the safety, tolerability, PK and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 cohorts, Cohort1 and Cohort2. At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort. The total number of subjects will depend upon the available data in each cohort and the Safety Review Committee (SRC)'s decision.

Study Period:

The study is expected to start in June 2020 and end in April 2021.

Number of Subjects:

6 to 12 evaluable subjects will be enrolled in this study to confirm the tolerability.

Treatments and treatment duration:

Subjects in each part will receive the study treatments as described below:

Cohort 1: Adavosertib 250 mg by mouth (PO) once daily (QD) for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle Cohort 2: Adavosertib 300 mg PO QD for 5 days ON and 2 days OFF for week 1 and 2 of a 21 days cycle Subjects will be allowed to continue adavosertib until disease progression, intolerable toxicity, or discontinuation criteria have been met.

Details
Condition Advanced Solid Tumours
Age 20years - 120years
Treatment Adavosertib (AZD1775)
Clinical Study IdentifierNCT04462952
SponsorAstraZeneca
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Japanese patients 20 years of age at the time of study entry
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0, 1
Adequate bone marrow reserve or organ function
Female patients who are not of child-bearing potential, and fertile females of childbearing potential who agree to use adequate contraceptive measures
Male patients should be willing to use barrier contraception
Predicted life expectancy 12 weeks
Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable
Measurable or non-measurable disease according to RECIST v1.1

Exclusion Criteria

Use of anti-cancer treatment drug 21 days or 5 half-lives (whichever is shorter) prior to the first dose of adavosertib
Use of an investigational drug during the past 30 days or 5 half-lives (whichever is longer) prior to the first dose of the study treatment
Common Terminology Criteria for Adverse Events (CTCAE) Grade >1 toxicity from prior therapy
Inability to swallow oral medication or any other condition that may impact adavosertib intake/absorption
Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases
Any of the cardiac diseases currently or within the last 6 months
Any underlying medical condition that would impair the patient's ability to receive study treatment
Other invasive malignancy within 5 years prior to the first dose of study drug except for non-invasive malignancies
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.